实用医学杂志
實用醫學雜誌
실용의학잡지
THE JOURNAL OF PRACTICAL MEDICINE
2014年
13期
2148-2150
,共3页
黄旭%闫昕%林贵军%高峰
黃旭%閆昕%林貴軍%高峰
황욱%염흔%림귀군%고봉
尼莫地平%面肌痉挛%面神经微血管减压术
尼莫地平%麵肌痙攣%麵神經微血管減壓術
니막지평%면기경련%면신경미혈관감압술
Nimodipine%Hemifacial spasm%Microvascular decompression
目的:探讨尼莫地平是否能减少面肌痉挛微血管减压术后面听神经相关并发症。方法:选择2011年5月至2013年10月期间,因面肌痉挛于我科行面神经微血管减压术患者220例,随机分为两组,治疗组110例,术后当日开始静脉泵入尼莫地平注射液(尼膜同)50 mg,泵速:2 mg/h,疗程3 d。3 d后改为口服尼莫地平片剂30 mg ,每天3次,疗程1周。对照组110例,术后不应用尼莫地平,其余治疗均与治疗组相同。统计两组患者术后3个月内面听神经并发症周围性面瘫及听力下降的发生情况并进行分析。结果:两组病例面肌痉挛治疗有效率均为100%,尼莫地平组术后周围性面瘫及听力下降的发生率较对照组降低(P <0.05)。结论:尼莫地平可显著降低面神经微血管减压术后周围性面瘫及听力下降的发生率。
目的:探討尼莫地平是否能減少麵肌痙攣微血管減壓術後麵聽神經相關併髮癥。方法:選擇2011年5月至2013年10月期間,因麵肌痙攣于我科行麵神經微血管減壓術患者220例,隨機分為兩組,治療組110例,術後噹日開始靜脈泵入尼莫地平註射液(尼膜同)50 mg,泵速:2 mg/h,療程3 d。3 d後改為口服尼莫地平片劑30 mg ,每天3次,療程1週。對照組110例,術後不應用尼莫地平,其餘治療均與治療組相同。統計兩組患者術後3箇月內麵聽神經併髮癥週圍性麵癱及聽力下降的髮生情況併進行分析。結果:兩組病例麵肌痙攣治療有效率均為100%,尼莫地平組術後週圍性麵癱及聽力下降的髮生率較對照組降低(P <0.05)。結論:尼莫地平可顯著降低麵神經微血管減壓術後週圍性麵癱及聽力下降的髮生率。
목적:탐토니막지평시부능감소면기경련미혈관감압술후면은신경상관병발증。방법:선택2011년5월지2013년10월기간,인면기경련우아과행면신경미혈관감압술환자220례,수궤분위량조,치료조110례,술후당일개시정맥빙입니막지평주사액(니막동)50 mg,빙속:2 mg/h,료정3 d。3 d후개위구복니막지평편제30 mg ,매천3차,료정1주。대조조110례,술후불응용니막지평,기여치료균여치료조상동。통계량조환자술후3개월내면은신경병발증주위성면탄급은력하강적발생정황병진행분석。결과:량조병례면기경련치료유효솔균위100%,니막지평조술후주위성면탄급은력하강적발생솔교대조조강저(P <0.05)。결론:니막지평가현저강저면신경미혈관감압술후주위성면탄급은력하강적발생솔。
Objective To investigate whether nimodipine could reduce complications after microvascular decompression in patients with hemifacial spasm. Methods 220 patients with hemifacial spasm , admitted into our hospital from May 2011 to Oct. 2013 , were all treated by microvascular decompression. They were divided randomly into two groups. Patients in the treatment group were treated with nimotop 50 mg/d after the operation for the first 3 days, then was orally taken 30 mg/d for a week. Patients in the control group were treated with the same after the operation without nimodipine. The postoperative complications including hearing deficit and peripheral facial paralysis were closely observed within three months after operation. Results The total effective rate was 100% in both groups. The incidence rate of peripheral facial paralysis and hearing deficit in treatment group was significant lower than that of the control group (P < 0.05). Conclusion Nimodipine has significant effect on reducing the incidence rate of peripheral facial paralysis and hearing deficit after microvascular decompression in patients with hemifacial spasm.